Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Review of the Historical Literature and Its Role in the Era of Targeted Molecular Therapy
Renal cell carcinoma presents with metastatic disease in approximately 30% cases. While surgical intervention remains the standard of care for organ confined disease, its role is limited in the management of metastatic disease. Over the last decade, cytoreductive nephrectomy prior to immunotherapy h...
Gespeichert in:
| Veröffentlicht in: | ISRN urology 2014, Vol.2014, p.717295-4 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4 |
|---|---|
| container_issue | |
| container_start_page | 717295 |
| container_title | ISRN urology |
| container_volume | 2014 |
| creator | Aslam, Muhammad Z. Matthews, P. N. |
| description | Renal cell carcinoma presents with metastatic disease in approximately 30% cases. While surgical intervention remains the standard of care for organ confined disease, its role is limited in the management of metastatic disease. Over the last decade, cytoreductive nephrectomy prior to immunotherapy has demonstrated significant improvement in overall survival for appropriately selected patients. This review summarizes the evidence for the role of cytoreductive nephrectomy in combination with immunotherapy and discusses its potential role in the current era of targeted molecular therapy. |
| doi_str_mv | 10.1155/2014/717295 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3922000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1540109356</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2895-115bb1064ea19265ac9a41e676b9aaf26ecd210cac1644e48e8a542f260c3e9f3</originalsourceid><addsrcrecordid>eNp9kUFr3DAQhU1paUKaU-9F0Etp2USSJdvqoRCWpAlsWgjbs5iVx7GCbW0lecP-lf7ayN1kaXKoDtKg-eYxvJdl7xk9YUzKU06ZOC1ZyZV8lR1yquhMVky-3te0PMiOQ7ij6UjKZSXeZgdcyKpUnB1mf-bb6DzWo4l2g-QHrluPJrp-SxrnyTVGCBGiNeQGB-jIHLt0gTd2cD18JWfpf2PxnriGxBbJpQ1Jz5qELmxED3H0SGCoyVUM5MZ1SOzwlzz3MA0twd9ixJpcp54ZO_Bk2aa59fZd9qaBLuDx43uU_bo4X84vZ4uf36_mZ4uZ4ZWSs2TDasVoIRCY4oUEo0AwLMpipQAaXqCpOaMGDCuEQFFhBVLw1KAmR9XkR9m3ne56XPVYGxyih06vve3Bb7UDq593BtvqW7fRueI8uZoEPj0KePd7xBB1b4NJRsGAbgyaSUEZVbksEvrxBXrnRp-MnSiaF5KV-UR92VHGuxA8NvtlGNVT7HqKXe9iT_SHf_ffs08hJ-DzDmjtUMO9_a_aA51_tZ8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1503651736</pqid></control><display><type>article</type><title>Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Review of the Historical Literature and Its Role in the Era of Targeted Molecular Therapy</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Aslam, Muhammad Z. ; Matthews, P. N.</creator><contributor>Autorino, R. ; Ku, J. H.</contributor><creatorcontrib>Aslam, Muhammad Z. ; Matthews, P. N. ; Autorino, R. ; Ku, J. H.</creatorcontrib><description>Renal cell carcinoma presents with metastatic disease in approximately 30% cases. While surgical intervention remains the standard of care for organ confined disease, its role is limited in the management of metastatic disease. Over the last decade, cytoreductive nephrectomy prior to immunotherapy has demonstrated significant improvement in overall survival for appropriately selected patients. This review summarizes the evidence for the role of cytoreductive nephrectomy in combination with immunotherapy and discusses its potential role in the current era of targeted molecular therapy.</description><identifier>ISSN: 2090-5807</identifier><identifier>ISSN: 2090-5815</identifier><identifier>EISSN: 2090-5815</identifier><identifier>DOI: 10.1155/2014/717295</identifier><identifier>PMID: 24587921</identifier><language>eng</language><publisher>Egypt: Hindawi Publishing Corporation</publisher><subject>Drug therapy ; Medical prognosis ; Morbidity ; Mortality ; Patients ; Response rates ; Review ; Studies ; Surgery</subject><ispartof>ISRN urology, 2014, Vol.2014, p.717295-4</ispartof><rights>Copyright © 2014 Muhammad Z. Aslam and P. N. Matthews.</rights><rights>Copyright © 2014 Muhammad Z. Aslam and P. N. Matthews. Muhammad Z. Aslam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2014 M. Z. Aslam and P. N. Matthews. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2895-115bb1064ea19265ac9a41e676b9aaf26ecd210cac1644e48e8a542f260c3e9f3</citedby><cites>FETCH-LOGICAL-c2895-115bb1064ea19265ac9a41e676b9aaf26ecd210cac1644e48e8a542f260c3e9f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922000/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922000/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,4010,27900,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24587921$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Autorino, R.</contributor><contributor>Ku, J. H.</contributor><creatorcontrib>Aslam, Muhammad Z.</creatorcontrib><creatorcontrib>Matthews, P. N.</creatorcontrib><title>Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Review of the Historical Literature and Its Role in the Era of Targeted Molecular Therapy</title><title>ISRN urology</title><addtitle>ISRN Urol</addtitle><description>Renal cell carcinoma presents with metastatic disease in approximately 30% cases. While surgical intervention remains the standard of care for organ confined disease, its role is limited in the management of metastatic disease. Over the last decade, cytoreductive nephrectomy prior to immunotherapy has demonstrated significant improvement in overall survival for appropriately selected patients. This review summarizes the evidence for the role of cytoreductive nephrectomy in combination with immunotherapy and discusses its potential role in the current era of targeted molecular therapy.</description><subject>Drug therapy</subject><subject>Medical prognosis</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Patients</subject><subject>Response rates</subject><subject>Review</subject><subject>Studies</subject><subject>Surgery</subject><issn>2090-5807</issn><issn>2090-5815</issn><issn>2090-5815</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUFr3DAQhU1paUKaU-9F0Etp2USSJdvqoRCWpAlsWgjbs5iVx7GCbW0lecP-lf7ayN1kaXKoDtKg-eYxvJdl7xk9YUzKU06ZOC1ZyZV8lR1yquhMVky-3te0PMiOQ7ij6UjKZSXeZgdcyKpUnB1mf-bb6DzWo4l2g-QHrluPJrp-SxrnyTVGCBGiNeQGB-jIHLt0gTd2cD18JWfpf2PxnriGxBbJpQ1Jz5qELmxED3H0SGCoyVUM5MZ1SOzwlzz3MA0twd9ixJpcp54ZO_Bk2aa59fZd9qaBLuDx43uU_bo4X84vZ4uf36_mZ4uZ4ZWSs2TDasVoIRCY4oUEo0AwLMpipQAaXqCpOaMGDCuEQFFhBVLw1KAmR9XkR9m3ne56XPVYGxyih06vve3Bb7UDq593BtvqW7fRueI8uZoEPj0KePd7xBB1b4NJRsGAbgyaSUEZVbksEvrxBXrnRp-MnSiaF5KV-UR92VHGuxA8NvtlGNVT7HqKXe9iT_SHf_ffs08hJ-DzDmjtUMO9_a_aA51_tZ8</recordid><startdate>2014</startdate><enddate>2014</enddate><creator>Aslam, Muhammad Z.</creator><creator>Matthews, P. N.</creator><general>Hindawi Publishing Corporation</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2014</creationdate><title>Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Review of the Historical Literature and Its Role in the Era of Targeted Molecular Therapy</title><author>Aslam, Muhammad Z. ; Matthews, P. N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2895-115bb1064ea19265ac9a41e676b9aaf26ecd210cac1644e48e8a542f260c3e9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Drug therapy</topic><topic>Medical prognosis</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Patients</topic><topic>Response rates</topic><topic>Review</topic><topic>Studies</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aslam, Muhammad Z.</creatorcontrib><creatorcontrib>Matthews, P. N.</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ISRN urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aslam, Muhammad Z.</au><au>Matthews, P. N.</au><au>Autorino, R.</au><au>Ku, J. H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Review of the Historical Literature and Its Role in the Era of Targeted Molecular Therapy</atitle><jtitle>ISRN urology</jtitle><addtitle>ISRN Urol</addtitle><date>2014</date><risdate>2014</risdate><volume>2014</volume><spage>717295</spage><epage>4</epage><pages>717295-4</pages><issn>2090-5807</issn><issn>2090-5815</issn><eissn>2090-5815</eissn><abstract>Renal cell carcinoma presents with metastatic disease in approximately 30% cases. While surgical intervention remains the standard of care for organ confined disease, its role is limited in the management of metastatic disease. Over the last decade, cytoreductive nephrectomy prior to immunotherapy has demonstrated significant improvement in overall survival for appropriately selected patients. This review summarizes the evidence for the role of cytoreductive nephrectomy in combination with immunotherapy and discusses its potential role in the current era of targeted molecular therapy.</abstract><cop>Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>24587921</pmid><doi>10.1155/2014/717295</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2090-5807 |
| ispartof | ISRN urology, 2014, Vol.2014, p.717295-4 |
| issn | 2090-5807 2090-5815 2090-5815 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3922000 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Drug therapy Medical prognosis Morbidity Mortality Patients Response rates Review Studies Surgery |
| title | Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Review of the Historical Literature and Its Role in the Era of Targeted Molecular Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T05%3A39%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytoreductive%20Nephrectomy%20for%20Metastatic%20Renal%20Cell%20Carcinoma:%20A%20Review%20of%20the%20Historical%20Literature%20and%20Its%20Role%20in%20the%20Era%20of%20Targeted%20Molecular%20Therapy&rft.jtitle=ISRN%20urology&rft.au=Aslam,%20Muhammad%20Z.&rft.date=2014&rft.volume=2014&rft.spage=717295&rft.epage=4&rft.pages=717295-4&rft.issn=2090-5807&rft.eissn=2090-5815&rft_id=info:doi/10.1155/2014/717295&rft_dat=%3Cproquest_pubme%3E1540109356%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1503651736&rft_id=info:pmid/24587921&rfr_iscdi=true |